KEY POINTS
OVERALL MARKET
FDA vaccine approval helped push the indices into the green today.
The market indices started the week in the green.
The market got off to a good start, boosted by the optimistic FDA approval of the Pfizer vaccine. The uncertainty surrounding the impact of the emerging delta variant has undoubtedly affected the market in the last few weeks. There were alsoprice rebounds in other sectors, such as oil, which was at its lowest level since May at the end of last week. The energy stock sector was up 3% throughout the trading session and contributed to today’s market’s gains. Overall, the market had an excellent start to the week. WE NEED YOU!
We value your opinion, help us make the Daily Roll even better!
Before we move on to today's stock analysis, I have a quick favor to ask. How do you like the Daily Roll shows? Do you like the format? Do you want it shorter, longer, or less frequent? What's the most important thing you'd wish the Daily Roll show to share with you that you cannot get anywhere else?
Click on this link or start with the following question to fill out a quick 2-minute feedback form for us! I would appreciate it if you can share your ideas. You can help us refine the Daily Roll by giving us a few pointers. You can open another tab to fill out the form, and I’ll still be here when you get back! WHAT'S UP?
Pfizer (PFE) had a big day between FDA approval and acquisitions.
Vaccines have been all over the media, and it’s been no different in the financial investments communities online. You’ve probably heard plenty about Pfizer (PFE), but today was a significant milestone for this pharma company. The COVID vaccine developed by Pfizer and BioNTech (BNTX) was given FDA approval today, the first in its class. Up until now, all vaccines had been distributed under emergency orders from governments to combat the rise in COVID cases. The FDA finally gave the green light to the company after reviewing six months of clinical data. Pfizer is up 2.5%, and BioNTech’s stock is up over 9%.
The race for vaccine development is still on, and if you’re interested in getting an overview of the companies involved, take a look at the COVID-19 Vaccine Race collection on Stock Card. While Pfizer stock may have been up slightly, the company was responsible for today's biggest gainer stock, Trillium Therapeutics (TRIL). Trillium topped Stock Card’s list of winning stocks with a whopping 188% jump. As it turns out, earlier today,Pfizer announced the acquisition of Trillium for $2.26 billion. Trillium Therapeutics will be a great addition to Pfizer’s efforts and research for treating cancer, making the company more robust and innovative. Both companies have been developing treatments for cancer, so it should be a smooth transition to combine operations. Regardless of Pfizer's status among the leading vaccine developers, this latest acquisition reminds investors just how broad the company's range of products is. Looking at its Stock Card, the company is profitable and generates more than $20 billion in free cash flow. And, even with the recent price increase, the stock is still hovering in an undervalued range with a 20.9 price-to-earnings ratio and 3.9 prices to book value ratio. Pfizer scores reasonably well across 11 criteria we use to evaluate whether a stock is a good fit for a dividend portfolio. To me, this is a stock worth a spot in a dividend-seeker portfolio. WHAT'S DOWN?
The Future of Retail: Should you buy into Target’s (TGT) dip?
While Target (TGT) stock managed to stay just barely in the green today, it has been falling steadily from an all-time high of $267 after the company released the financial results for this past quarter. Its earnings report on the 18th beat estimates, but investors weren’t too keen on its growth outlook.
Aside from its price action, Target is doing a great job at innovating the retail business, particularly when it comes to brick-and-mortar shopping. A story caught my eye today that is an excellent example of this. Disney (DIS) is adding over 100 new mini-stores inside Target locations, building off the 53 already operating while closing many standalone stores. If you’ve been inside a Target recently, you may have noticed Starbucks (SBUX) or Ulta Beauty (ULTA) shops as well. The company is seeing the opportunity for more profit and traffic by subleasing parts of its stores to other companies. This reminds me a lot of the shopping mall business model. While shopping malls are struggling, the store-in-a-store concept seems to be taking off. Target already brings traffic in for core household items and then monetizes the traffic by selling high-value items from Disney and Ulta Beauty. Macy’s (M) is also bringing back the classic toy store Toys R Us in the same fashion, with over 400 locations planned next year. Both Target and Macy stocks can be found on the Future of Shopping collection on our platform, and for a good reason. Specifically, on Target's Stock Card, you can see it is now reasonably priced with a price to earnings ratio of 20 and price to sales ratio of slightly higher than 1, which is surprising for a retailer with such strong operations and new innovative ideas like the store-in-a-store idea we just discussed. Like Pfizer, Target is also a dividend-paying stock with reasonably well scores across all 11 dividend portfolio criteria. And, just like Pfizer, Target earns a spot on a dividend-seeker’s portfolio. WE NEED YOU!
We value your opinion, help us make the Daily Roll even better!
Folks, like I said earlier, we need your help to improve the Daily Roll show. It's a quick survey and only takes a few minutes! It means a lot to us to have a show that you find useful and worth your time.
You can click on this link here to fill out our quick 2-min feedback form. Your opinion means the world to us, so I would appreciate it if you can share your ideas. Thanks for taking the time to lend us feedback! WANT TO RECEIVE THIS DAILY STOCK MARKET RECAP IN YOUR MAILBOX?Comments are closed.
|
Archives
February 2022
Categories
All
|
RSS Feed